Market revenue in 2023 | USD 2,883.6 million |
Market revenue in 2030 | USD 4,734.3 million |
Growth rate | 7.3% (CAGR from 2023 to 2030) |
Largest segment | Liquid delivery device |
Fastest growing segment | Liquid Delivery Device |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Powder delivery device, Liquid Delivery Device, Pressurized Metered Dose Inhaler |
Key market players worldwide | GSK PLC ADR, Teva Pharmaceutical Industries Ltd, AptarGroup Inc, UCB SA, Teleflex Inc, 3M Co, OptiNose Inc, Bespak, Intersect ENT |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intranasal drug and vaccine delivery market will help companies and investors design strategic landscapes.
Liquid delivery device was the largest segment with a revenue share of 43.36% in 2023. Horizon Databook has segmented the Japan intranasal drug and vaccine delivery market based on powder delivery device, liquid delivery device, pressurized metered dose inhaler covering the revenue growth of each sub-segment from 2018 to 2030.
The intranasal drug and vaccine delivery market in Japan held 21.1% of share in 2021 owing to rising R&D efforts by key players operating in the market to deliver novel products. Japan is a member of the OECD countries and an important member of the Asia Pacific trade block.
Increasing various government initiatives regarding technological advancement and balancing the effective regulatory compliance requirement are also among contributing factors expected to boost regional growth. Thus, the abovementioned factors are further expected to boost market growth.
Increasing awareness about nasal drug delivery systems, especially for allergic rhinitis, is one of the key factors driving the market. For instance, a specific Japanese guideline for allergic rhinitis was prepared in 2017 to understand drug delivery and its proper application for treatment.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan intranasal drug and vaccine delivery market , including forecasts for subscribers. This country databook contains high-level insights into Japan intranasal drug and vaccine delivery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account